#
|
Title
|
Authors
|
Affiliations
|
Keywords
|
P207
|
Phase II Study of Anti-CD3 x Anti-HER2/neu (HERBi) Armed Activated T Cells (ATC) after Neoadjuvant Chemotherapy in Patients with HER2/neu(0-2+)-Negative Stage II-III Breast Cancer
|
Naresh Bumma1, Andrew Kin1, Judith Abrams1, Abhinav Deol1, Amy Weise1, Archana Thakur2, Lawrence Lum2
|
1Wayne State University/Karmanos Cancer Institute, Detroit, MI, USA 2University of Virginia Cancer Center, Charlottesville, VA, USA
|
Adoptive immunotherapy | T cell | Solid tumors | Targeted therapy | Clinical trial | CAR T cells
|
P208
|
Safety, efficacy and biology of the gp100 TCR-based bispecific T cell redirector, IMCgp100 in advanced uveal melanoma in two Phase 1 trials
|
Richard Carvajal1, Takami Sato2, Alexander N. Shoushtari3, Joseph Sacco4, Paul Nathan5, Marlana Orloff2, Pippa Corrie6, Neil Steven7, Jeff Evans8, Jeffrey Infante9, Mario Sznol10, Clive Mulatero11, Omid Hamid12, Leonel Hernandez-Aya13, Nicola Little14, Cheryl McAlpine15, David Krige15, Namir J. Hassan16, Sanjay Patel16, Ann-Marie Hulstine17, Christina M. Coughlin17, Mark R. Middleton18
|
1Columbia University Medical Center, New York, NY, USA 2Thomas Jefferson University, Philadelphia, PA, USA 3Memorial Sloan Kettering Cancer Center, New York, NY, USA 4Clatterbridge Cancer Center, Liverpool, United Kingdom 5Mount Vernon Cancer Center, Middlesex, United Kingdom 6Addenbroke's Hospital, Cambridge, United Kingdom 7University of Birmingham, Birmingham, United Kingdom 8Beatson Cancer Centre, Glasgow, United Kingdom 9Sarah Cannon Cancer Research Institute, Nashville, TN, USA 10Yale University Cancer Center, New Haven, CT, USA 11Spire Leeds Hospital, West Yorkshire, United Kingdom 12The Angeles Clinic, Santa Monica, CA, USA 13Siteman Cancer Center, St. Louis, MO, USA 14Department of Biostatistics, Alderley, United Kingdom 15Biomarkers, Milton, United Kingdom 16Immunocore, Ltd., Milton, United Kingdom 17Immunocore, Ltd., Conshohocken, PA, USA 18University of Oxford, Oxford, United Kingdom
|
Solid tumors | Clinical trial | Tumor microenvironment
|
P209
|
Randomized trial of autologous dendritic cell vaccines versus autologous tumor cell vaccines in metastatic melanoma
|
Robert Dillman1, Edward McClay2, Thomas Amatruda3, Andrew Cornforth4, Carol Depriest5
|
1Hoag Cancer Institute, Newport Beach, CA, USA 2Institute for Melanoma Research & Education, Encinitas, CA, USA 3Minnesota Oncology, Fridley, MN, USA 4TCR2 Therapeutics, Cambridge, MA, USA 5Hoag Hospital, Franklin, TN, USA
|
Antigen presenting cells | Dendritic cell | Neoantigens | Clinical trial | Vaccine | Tumor antigens
|
P210
|
Pilot trial of sipuleucel-T, with or without pTVG-HP DNA vaccine, in patients with metastatic, castration-resistant prostate cancer (mCRPC)
|
Ellen Wargowski1, Laura Johnson1, Glenn Liu1, Jens Eickhoff1, Mary Jane Staab1, Douglas McNeel1
|
1University of Wisconsin, Madison, WI, USA
|
Tumor antigens | Immune monitoring | Clinical trial | Vaccine
|
P211
|
Phase 2 Trial Exploring Allogeneic Vaccine Therapy in Late-Stage, Second-Line Non-Small Cell Lung Cancer
|
Christopher Meldrum1, Eckhard Podack2, Jonathan Serody3, Varada Bidargaddi3
|
1Pique Therapeutics, Inc., Durham, NC, USA 2Pique Therapeutics, Inc., Coconut Grove, FL, USA 3University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
|
Vaccine | Clinical trial
|
P212
|
Tumor immune infiltration in patients with early stage breast cancer after preoperative treatment with IRX-2.
|
David B. Page1, Joanna Pucilowska1, Nikki Moxon1, Staci Mellinger1, Alison Conlin1, James Imatani1, Shaghayegh Aliabadi-Wahle1, Valerie Conrad1, Maritza Martel1, Kelly Perlewitz1, Neil L. Berinstein2, James E. Egan2, William L. Redmond1, Walter J. Urba1
|
1EACRI, Portland, OR, USA 2IRX Therapeutics, NY, NY, USA
|
Biomarkers | Clinical study | Immune monitoring | Immune toxicity | Tumor infiltrating lymphocytes (TILs) | T cell | Solid tumors | Cytokine | Clinical trial | Chemokine
|
P213
|
Efficacy and tolerability of tremelimumab in locally advanced or metastatic urothelial carcinoma
|
Padmanee Sharma1, Joo Hyuk Sohn2, Sang Joon Shin2, Do-Youn Oh3, Bhumsuk Keam3, Hyo Jin Lee4, Jean-Luc Canon5, Ewa Kalinka-Warzocha6, Marlies Langenberg7, James Allison8, Yong Ben9, Ritesh Kataria9, Salvatore Ferro9, Kobby Asubonteng9, Luc Dirix10
|
1MD Anderson Cancer Center, Houston, TX, USA 2Yonsei University Severance Hospital, Seoul, Republic of Korea 3Seoul National University Hospitial, Seoul, Republic of Korea 4Chungnam National University Hospital, Daejeon, Republic of Korea 5Grand Hopital de Charleroi, Charleroi, Belgium 6Polish Mother's Memorial Hospital-Research Institute, Lodz, Poland 7University Medical Center Utrecht, Utrecht, Netherlands 8University of Texas MD Anderson Cancer Center, Houston, TX, USA 9AstraZeneca, Gaithersburg, MD, USA 10St-Augustinus Ziekenhuis, Wilrijk, Belgium
|
Clinical trial | Checkpoint blockade | Solid tumors | Clinical study | Targeted therapy
|
P214
|
T cells Transfer and Boost Anti-Breast Cancer Immunity after Stem Cell Transplant
|
Lawrence G Lum1, Archana Thakur1, Sri Vidya Kondadasula2, Joseph P Uberti2, Voravit Ratanatharathorn2
|
1University of Virginia, Charlottesville, VA, USA 2Karmanos Cancer Institute, Detroit, MI, USA
|
Adoptive immunotherapy | Clinical study | Solid tumors
|
P215
|
Randomized phase I/II pilot study using all-trans retinoic acid to target myeloid-derived suppressor cells in melanoma patients undergoing Ipilimumab therapy
|
Richard P Tobin1, Kimberly R Jordan1, William A Robinson1, Dana Davis1, Virginia F Borges1, Rene Gonzalez1, Karl D Lewis1, Martin D McCarter1
|
1University of Colorado Anschutz Medical Campus, Aurora, CO, USA
|
Immune tolerance | Myeloid cells | Granulocyte | Immune monitoring | MDSC | T cell | Monocyte/Macrophage | Clinical trial | Immune suppression | Checkpoint blockade
|
P216
|
Long-term survival in patients with advanced melanoma, renal cell carcinoma, or non-small cell lung cancer treated with nivolumab
|
Suzanne L. Topalian1, F. Stephen Hodi2, Julie R. Brahmer3, Scott N. Gettinger4, David C. Smith5, David F. McDermott6, John D. Powderly7, Jeffrey A. Sosman8, Michael B. Atkins9, David R. Spigel10, Scott J. Antonia11, Alexander Drilon12, Rafia Bhore13, Fareeda Hosein13, Mario Sznol4
|
1Johns Hopkins Bloomberg~Kimmel Institute for Cancer Immunotherapy, Baltimore, MD, USA 2Dana-Farber Cancer Institute, Boston, MA, USA 3Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA 4Yale Cancer Center, New Haven, CT, USA 5University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA 6Beth Israel Deaconess Medical Center, Dana-Farber/Harvard Cancer Center, Boston, MA, USA 7Carolina Bio-Oncology Institute, Huntersville, NC, USA 8Northwestern University Medical Center, Chicago, IL, USA 9Georgetown University Medical Center - Lombardi Comprehensive Cancer Center, Washington, DC, USA 10Lung Cancer Research Program, Sarah Cannon Research Institute, Nashville, TN, USA 11Moffitt Cancer Center, Tampa, FL, USA 12Memorial Sloan Kettering Cancer Hospital, New York, NY, USA 13Bristol-Myers Squibb, Princeton, NJ, USA
|
Clinical study | Checkpoint blockade | Clinical trial | Solid tumors
|
P217
|
Clinical Outcomes for the Phase 2, Single-Arm, Multicenter Trial of JCAR015 in Adult B-ALL (ROCKET Study)
|
Daniel J. DeAngelo1, Armin Ghobadi1, Jae H. Park3, Shira N. Dinner4, Gabriel N. Mannis5, Matthew A. Lunning6, Samer K. Khaled7, Amir T. Fathi8, Ivana Gojo9, Eunice S. Wang10, Michael R. Bishop11, Heather Hughes12, Samuel Blackman12, James Whitmore12, Nikolaus S. Trede12, Mark Gilbert12, William G. Wierda13
|
1Dana-Farber Cancer institute, Boston, MA, USA 3Memorial Sloan-Kettering Cancer Center, New York, NY, USA 4Northwestern Medicine, Feinberg School of Medicine, Chicago, IL, USA 5UCSF Helen Diller Family Comprehensive Cancer Center, San Fransisco, CA, USA 6Unversity of Nebraska Medical Center, Omaha, NE, USA 7City of Hope, Duarte, CA, USA 8Massachusetts General Hospital, Boston, MA, USA 9Johns Hopkins Medicine, Baltimore, MD, USA 10Roswell Park Cancer Institute, Buffalo, NY, USA 11The University of Chicago Medicine, Chicago, IL, USA 12Juno Therapeutics, Inc., Seattle, WA, USA 13The University of Texas MD Anderson Cancer Center, Houston, TX, USA
|
T cell | CAR T cells | Clinical trial | Chemotherapy | B cell
|